195 related articles for article (PubMed ID: 19808223)
1. The journey from vitamin D-resistant rickets to the regulation of renal phosphate transport.
Levine BS; Kleeman CR; Felsenfeld AJ
Clin J Am Soc Nephrol; 2009 Nov; 4(11):1866-77. PubMed ID: 19808223
[TBL] [Abstract][Full Text] [Related]
2. Fibrous dysplasia, phosphate wasting and fibroblast growth factor 23.
Imel EA; Econs MJ
Pediatr Endocrinol Rev; 2007 Aug; 4 Suppl 4():434-9. PubMed ID: 17982392
[TBL] [Abstract][Full Text] [Related]
3. Emerging role of a phosphatonin in mineral homeostasis and its derangements.
Bielesz B
Eur J Clin Invest; 2006 Aug; 36 Suppl 2():34-42. PubMed ID: 16884396
[TBL] [Abstract][Full Text] [Related]
4. Fibroblast growth factor 23 and its receptors.
Yu X; White KE
Ther Apher Dial; 2005 Aug; 9(4):308-12. PubMed ID: 16076372
[TBL] [Abstract][Full Text] [Related]
5. FGF23, PHEX, and MEPE regulation of phosphate homeostasis and skeletal mineralization.
Quarles LD
Am J Physiol Endocrinol Metab; 2003 Jul; 285(1):E1-9. PubMed ID: 12791601
[TBL] [Abstract][Full Text] [Related]
6. Three novel mutations of the PHEX gene in three Chinese families with X-linked dominant hypophosphatemic rickets.
Xia W; Meng X; Jiang Y; Li M; Xing X; Pang L; Wang O; Pei Y; Yu LY; Sun Y; Hu Y; Zhou X
Calcif Tissue Int; 2007 Dec; 81(6):415-20. PubMed ID: 18046499
[TBL] [Abstract][Full Text] [Related]
7. FGF23 and disorders of phosphate homeostasis.
Yu X; White KE
Cytokine Growth Factor Rev; 2005 Apr; 16(2):221-32. PubMed ID: 15863037
[TBL] [Abstract][Full Text] [Related]
8. The role of fibroblast growth factor 23 for hypophosphatemia and abnormal regulation of vitamin D metabolism in patients with McCune-Albright syndrome.
Yamamoto T; Imanishi Y; Kinoshita E; Nakagomi Y; Shimizu N; Miyauchi A; Satomura K; Koshiyama H; Inaba M; Nishizawa Y; Jüppner H; Ozono K
J Bone Miner Metab; 2005; 23(3):231-7. PubMed ID: 15838626
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic effects of anti-FGF23 antibodies in hypophosphatemic rickets/osteomalacia.
Aono Y; Yamazaki Y; Yasutake J; Kawata T; Hasegawa H; Urakawa I; Fujita T; Wada M; Yamashita T; Fukumoto S; Shimada T
J Bone Miner Res; 2009 Nov; 24(11):1879-88. PubMed ID: 19419316
[TBL] [Abstract][Full Text] [Related]
10. Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23) in hypophosphatemic patients: proposal of diagnostic criteria using FGF23 measurement.
Endo I; Fukumoto S; Ozono K; Namba N; Tanaka H; Inoue D; Minagawa M; Sugimoto T; Yamauchi M; Michigami T; Matsumoto T
Bone; 2008 Jun; 42(6):1235-9. PubMed ID: 18396126
[TBL] [Abstract][Full Text] [Related]
11. Renal phosphate loss in hereditary and acquired disorders of bone mineralization.
Bielesz B; Klaushofer K; Oberbauer R
Bone; 2004 Dec; 35(6):1229-39. PubMed ID: 15589204
[TBL] [Abstract][Full Text] [Related]
12. Phosphatonins: From Discovery to Therapeutics.
Kritmetapak K; Kumar R
Endocr Pract; 2023 Jan; 29(1):69-79. PubMed ID: 36210014
[TBL] [Abstract][Full Text] [Related]
13. X-linked hypophosphatemic rickets and craniosynostosis.
Murthy AS
J Craniofac Surg; 2009 Mar; 20(2):439-42. PubMed ID: 19242361
[TBL] [Abstract][Full Text] [Related]
14. [Endocrine diseases accompanied by hypophosphatemia or hyperphosphatemia].
Nakayama K
Nihon Rinsho; 2006 Sep; Suppl 3():542-52. PubMed ID: 17022606
[No Abstract] [Full Text] [Related]
15. Co-existence of X-linked hypophosphatemic rickets (XLH) and primary hyperparathyroidism: case report and review of the literature.
Tournis ST; Giannikou PV; Paspati IN; Katsalira EA; Voskaki IC; Lyritis GP
J Musculoskelet Neuronal Interact; 2005 Jun; 5(2):150-4. PubMed ID: 15951631
[TBL] [Abstract][Full Text] [Related]
16. Renal phosphate handling in human--what can we learn from hereditary hypophosphataemias?
Amatschek S; Haller M; Oberbauer R
Eur J Clin Invest; 2010 Jun; 40(6):552-60. PubMed ID: 20412291
[TBL] [Abstract][Full Text] [Related]
17. Role of fibroblast growth factor 23 in phosphate homeostasis and pathogenesis of disordered mineral metabolism in chronic kidney disease.
Stubbs J; Liu S; Quarles LD
Semin Dial; 2007; 20(4):302-8. PubMed ID: 17635819
[TBL] [Abstract][Full Text] [Related]
18. Genetic advances, biochemical and clinical features and critical approach to treatment of patients with X-linked hypophosphatemic rickets.
Baroncelli GI; Bertelloni S; Sodini F; Galli L; Vanacore T; Fiore L; Saggese G
Pediatr Endocrinol Rev; 2004 Jun; 1(4):361-79. PubMed ID: 16437029
[TBL] [Abstract][Full Text] [Related]
19. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
20. Hypophosphatemic rickets.
Baroncelli GI; Toschi B; Bertelloni S
Curr Opin Endocrinol Diabetes Obes; 2012 Dec; 19(6):460-7. PubMed ID: 23108197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
